102 related articles for article (PubMed ID: 7898711)
1. Clinical and immunologic follow-up study of patients with neurocysticercosis after treatment with praziquantel.
Rolfs A; Mühlschlegel F; Jansen-Rosseck R; Martins AR; Bedaque EA; Tamburus WM; Pedretti L; Schulte G; Feldmeier H; Kremsner P
Neurology; 1995 Mar; 45(3 Pt 1):532-8. PubMed ID: 7898711
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to the metacestode of Taenia solium in the saliva from patients with neurocysticercosis.
Acosta E
J Clin Lab Anal; 1990; 4(2):90-4. PubMed ID: 2313474
[TBL] [Abstract][Full Text] [Related]
3. Praziquantel treatment of brain and muscle porcine Taenia solium cysticercosis. 2. Immunological and cytogenetic studies.
Flisser A; Gonzalez D; Plancarte A; Ostrosky P; Montero R; Stephano A; Correa D
Parasitol Res; 1990; 76(7):640-2. PubMed ID: 2217129
[No Abstract] [Full Text] [Related]
4. Praziquantel treatment of porcine brain and muscle Taenia solium cysticercosis. 3. Effect of 1-day treatment.
Torres A; Plancarte A; Villalobos AN; de Aluja AS; Navarro R; Flisser A
Parasitol Res; 1992; 78(2):161-4. PubMed ID: 1557328
[No Abstract] [Full Text] [Related]
5. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
6. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
[TBL] [Abstract][Full Text] [Related]
8. Humoral immune response in patients with cerebral parenchymal cysticercosis treated with praziquantel.
Estañol B; Juárez H; Irigoyen Mdel C; González-Barranco D; Corona T
J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):254-7. PubMed ID: 2703841
[TBL] [Abstract][Full Text] [Related]
9. [ELISA (IgG and IgM) of the CSF and serum in neurocysticercosis under treatment with praziquantel: comparison with complement fixation reactions and immunofluorescence].
Livramento JA; Costa JM; Machado LR; Nóbrega JP; Spina-França A
Arq Neuropsiquiatr; 1985 Sep; 43(3):267-74. PubMed ID: 3911928
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.
Ott M; Demisch L; Engelhardt W; Fischer PA
J Neurol; 1993 Dec; 241(2):108-14. PubMed ID: 8138825
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an IgG-ELISA strategy using Taenia solium metacestode somatic and excretory-secretory antigens for diagnosis of neurocysticercosis revealing biological stage of the larvae.
Sahu PS; Parija SC; Narayan SK; Kumar D
Acta Trop; 2009 Apr; 110(1):38-45. PubMed ID: 19183550
[TBL] [Abstract][Full Text] [Related]
12. [A cerebrospinal fluid syndrome in neurocysticercosis].
Livramento JA
Arq Neuropsiquiatr; 1987 Sep; 45(3):261-75. PubMed ID: 2449880
[TBL] [Abstract][Full Text] [Related]
13. Praziquantel in the treatment of neurocysticercosis: long-term follow-up.
Sotelo J; Torres B; Rubio-Donnadieu F; Escobedo F; Rodriguez-Carbajal J
Neurology; 1985 May; 35(5):752-5. PubMed ID: 3990975
[TBL] [Abstract][Full Text] [Related]
14. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
15. [Neurocysticercosis. II. Evaluation of treatment with praziquantel].
Takayanagui OM
Arq Neuropsiquiatr; 1990 Mar; 48(1):11-5. PubMed ID: 2198859
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.
Nassonov EL; Samsonov MY; Tilz GP; Beketova TV; Semenkova EN; Baranov A; Wachter H; Fuchs D
J Rheumatol; 1997 Apr; 24(4):666-70. PubMed ID: 9101499
[TBL] [Abstract][Full Text] [Related]
17. [Cerebral cysticercosis. A report on the treatment with praziquantel].
Meyer-Wahl JG; Maier-Metz F
Fortschr Med; 1984 Mar; 102(12):336-9. PubMed ID: 6714907
[TBL] [Abstract][Full Text] [Related]
18. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.
Shaw CE; Dunbar PR; Macaulay HA; Neale TJ
J Neurol; 1995 Jan; 242(2):53-8. PubMed ID: 7707089
[TBL] [Abstract][Full Text] [Related]
19. The treatment of neurocysticercosis with praziquantel.
Vanijanonta S; Bunnag D; Riganti M
Southeast Asian J Trop Med Public Health; 1991 Dec; 22 Suppl():275-8. PubMed ID: 1822905
[TBL] [Abstract][Full Text] [Related]
20. Treatment of neurocysticercosis.
Joubert J; Jenni WK
S Afr Med J; 1990 Jan; 77(1):27-30. PubMed ID: 2294609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
